UnitedHealth Group was supposed to be the safest large-cap stock in healthcare. With 53 million members, $400 billion in annual revenue, and a vertically integrated empire spanning insurance, pharmacy benefits, and physician services, the company had earned its status as a Dow Jones Industrial Average component and a core holding in virtually every institutional healthcare portfolio. That thesis is now under severe stress.
The Numbers Tell the Story
UnitedHealth shares have plunged more than 45% since the start of 2026, erasing roughly $250 billion in market capitalization and making it one of the worst-performing stocks in the entire S&P 500. The decline has been so severe that analysts at Mizuho have publicly raised the possibility of UnitedHealth being removed from the Dow Jones Industrial Average, a move that would compound selling pressure from index funds forced to rebalance.
The collapse is not the result of a single event. It is the accumulation of a cascade of crises that began in late 2024 and have progressively worsened: the tragic murder of CEO Brian Thompson in December 2024, the abrupt departure of his successor Andrew Witty in May 2025, suspended earnings guidance due to surging medical costs, and now the most serious threat of all, a federal criminal investigation.
Inside the DOJ Probe
The Department of Justice's criminal investigation into UnitedHealth began as a focused inquiry into Medicare Advantage billing practices. Medicare Advantage is the privatized version of Medicare in which the government pays insurers a per-member monthly fee adjusted by the health status, or "risk score," of each enrollee. The sicker the patient appears on paper, the higher the payment from the Centers for Medicare and Medicaid Services.
The core allegation is straightforward: UnitedHealth systematically inflated the risk scores of its Medicare Advantage members by adding diagnoses that were not supported by clinical evidence, thereby collecting billions in excess payments from the federal government.
According to reporting from the Wall Street Journal, Medicare data from 2019 through 2021 showed that patients seen by UnitedHealth-employed physicians were diagnosed with certain rare conditions, including hyperaldosteronism, a hormonal disorder, at rates significantly higher than the national average. In-home health assessments conducted by UnitedHealth nurses reportedly triggered an average of $2,735 in additional federal payments per visit.
The Probe Keeps Expanding
What began as an investigation into Medicare Advantage billing has now grown into a multi-tentacled inquiry touching nearly every corner of UnitedHealth's business. In January 2026, DOJ attorneys reportedly began interviewing former UnitedHealth-employed clinicians about their experiences with the company's coding practices. One former nurse practitioner told investigators that she was pressured to add diagnoses to patient records without supporting laboratory tests or clinical examinations.
The investigation has also expanded to include Optum Rx, UnitedHealth's pharmacy benefits management arm, and is now examining how the company reimburses the tens of thousands of physicians employed through its Optum Health division. The breadth of the probe suggests that investigators are looking at systemic practices rather than isolated incidents.
"When a criminal investigation starts in one division and spreads to three, that is not a fishing expedition. That is prosecutors following the evidence wherever it leads."
— A former federal healthcare fraud prosecutor now in private practice
The Financial Exposure Is Staggering
UnitedHealth's Medicare Advantage business generates more than $130 billion in annual revenue, making it the company's largest single revenue stream. If the DOJ concludes that billing practices were systematically fraudulent, the potential penalties under the False Claims Act could run into the tens of billions of dollars. Criminal convictions could also trigger exclusion from federal healthcare programs, an outcome that would be existential for a company that derives the majority of its revenue from government contracts.
The company has launched an internal review and maintains confidence in its compliance and documentation practices. UnitedHealth has pointed to independent audits by CMS that it says confirm its practices are "among the most accurate in the industry." But the gap between what CMS audits measure and what a criminal investigation examines is significant, and investors are pricing in the worst-case scenario.
The Leadership Vacuum Makes Everything Harder
Navigating a crisis of this magnitude requires experienced, trusted leadership, and UnitedHealth is operating without it. The company is now on its third CEO in less than 18 months. The board has been in damage-control mode since Thompson's death, and morale among the company's 440,000 employees has been described by insiders as the lowest in the company's history.
The revolving door at the top has also complicated the company's ability to cooperate with investigators. Defense attorneys in healthcare fraud cases typically want a single, authoritative point of contact between the company and the DOJ. When leadership keeps changing, so does the strategy, the messaging, and the timeline for resolution.
What It Means for 53 Million Members
For the tens of millions of Americans who receive their health insurance through UnitedHealth, the immediate impact is minimal. Insurance contracts are binding, provider networks remain in place, and claims continue to be processed. But if the investigation results in significant financial penalties or operational restrictions, the long-term effects could include narrower networks, higher premiums, and reduced benefits as the company attempts to rebuild its financial position.
Medicare Advantage members should pay particular attention. If CMS determines that UnitedHealth's risk scores were inflated, the agency could claw back overpayments and adjust future capitation rates downward. That adjustment would pressure UnitedHealth to cut costs somewhere, and historically, those cuts flow downstream to patients in the form of reduced supplemental benefits like dental, vision, and hearing coverage.
The Investment Case Going Forward
At its current price, UnitedHealth trades at roughly 10 times forward earnings, a valuation that would have been unthinkable a year ago for a company that typically commanded a 20-plus multiple. Value investors are beginning to circle, arguing that the stock has overshot to the downside and that the company's diversified business model can absorb even significant legal penalties.
But the bears counter that a criminal probe of this scope creates binary risk that is nearly impossible to model. The range of outcomes spans from a negotiated settlement with manageable fines to criminal convictions that fundamentally alter the company's ability to participate in government healthcare programs. Until prosecutors signal which direction the case is heading, that uncertainty will keep a lid on the stock.
For investors, UnitedHealth is a reminder that even the most dominant companies in the most defensive sectors are not immune to legal risk. The healthcare industry generates a quarter of its revenue from the federal government, and when the government decides to investigate how that money is being spent, no amount of market dominance provides protection.
